Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $6.2 million.

  • Janux Therapeutics' Change in Accured Expenses rose 3511.92% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year increase of 4141.23%. This contributed to the annual value of $4.4 million for FY2024, which is 75280.24% up from last year.
  • Per Janux Therapeutics' latest filing, its Change in Accured Expenses stood at $6.2 million for Q3 2025, which was up 3511.92% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Change in Accured Expenses ranged from a high of $6.2 million in Q3 2025 and a low of -$2.0 million during Q3 2023
  • Moreover, its 5-year median value for Change in Accured Expenses was $1.0 million (2022), whereas its average is $1.1 million.
  • As far as peak fluctuations go, Janux Therapeutics' Change in Accured Expenses soared by 60586.8% in 2022, and later tumbled by 48356.81% in 2024.
  • Janux Therapeutics' Change in Accured Expenses (Quarter) stood at $1.9 million in 2021, then plummeted by 47.68% to $1.0 million in 2022, then plummeted by 57.61% to $426000.0 in 2023, then crashed by 483.57% to -$1.6 million in 2024, then soared by 478.15% to $6.2 million in 2025.
  • Its last three reported values are $6.2 million in Q3 2025, $2.9 million for Q2 2025, and $1.7 million during Q1 2025.